Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago

Ciprofibrate

Anti-hypertensive Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Hyperlipidemia

Ciprofibrate is used as an add-on to diet, exercise and weight reduction in two situations. The first is severe hypertriglyceridemia, with or without low HDL cholesterol. The second is mixed hyperlipidemia, when a statin is contraindicated or the patient can't tolerate it.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Ciprofibrate lowers both LDL and VLDL, and so it brings down the triglyceride and cholesterol carried in these lipoprotein fractions. It also raises HDL cholesterol. The medicine works well for hyperlipidemia where plasma concentrations of LDL and VLDL are high. There is evidence that treatment with fibrates may reduce coronary heart disease events.

Pregnancy & Breastfeeding

Nothing shows that Ciprofbrate is teratogenic, but animal teratogenicity tests did show signs of toxicity at high doses. There are no data on its use in human pregnancy, so Ciprofbrate is contraindicated during pregnancy. Data on its use during lactation are also missing, and for that reason it is contraindicated in nursing mothers too.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Adults: the recommended dose is Ciprofbrate 100 mg per day, and this dose should not be exceeded. Patients with renal insufficiency: in moderate renal impairment (creatinine clearance 30 to 80 ml/min/1.73 m2), the dose should be reduced to one tablet every other day. These patients should be monitored carefully. Ciprofbrate should not be used in severe renal impairment (creatinine clearance <30 ml/min/1.73 m2). Patients with hepatic insufficiency: use Ciprofbrate with caution in people with impaired liver function. Stop the treatment if AST and ALT levels rise to more than 3 times the upper limit of normal, or if there is evidence of cholestatic liver injury. Elderly: the dose is the same as for adults, but take precautions for age more than 70 years. Paediatric population: Ciprofbrate is not recommended, because safety and efficacy in children have not been established.